The Eigen Therapeutics team. Front row (L-R): Senior scientist Anukriti Dhar, associate scientist Molly Volkman, CSO Kathryn Vanderlaag. Back row (L-R): Lead engineer Erik Werner, CEO Transon Nguyen, CTO Kamran Ali
December 8, 2022 04:00 AM EST
Financing
Startups

Prim­ing ther­a­py biotech emerges from stealth with seed fund­ing — and on a hunt for part­ners

Katherine Lewin

News Reporter

At Eigen Ther­a­peu­tics, the goal is to make can­cer treat­ment more ef­fec­tive. But not by mak­ing tar­get­ed drugs.

With $7 mil­lion in seed fund­ing an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times